TUMOR-INFILTRATING T-LYMPHOCYTE (T-TIL) RESPONSE IS DEFICIENT IN B-CELL NHL ARISING IN IMMUNOCOMPROMISED (IC) HOSTS (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

TUMOR-INFILTRATING T-LYMPHOCYTE (T-TIL) RESPONSE IS DEFICIENT IN B-CELL NHL ARISING IN IMMUNOCOMPROMISED (IC) HOSTS (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 10:A940 1991. Unique Identifier : AIDSLINE ICDB/91671449
List AF; Grogan TM; Spier CM; Miller TP; Arizona Cancer Center, Tucson, AZ

Abstract: Organ allograft recipients and HIV-infected patients (pts) have a high incidence of aggressive B-cell NHL. Factors contributing to the pathogenesis of B-cell neoplasia in such pts and poor outcome with conventional cytotoxic therapy remain unclear. We previously reported that tumor immunobiologic features and host T-TIL response are important determinants of outcome in pts with sporadic-B, diffuse large cell (DLC) NHL. To determine relevant biologic determinants in IC-hosts, we assessed T-TIL number in tissue sections by immunohistochemistry using the monoclonal antibodies Leu-2 and -3 in 18 consecutive B-cell NHLs from IC-pts, and compared results to those from 83 sporadic DLC-NHLs of B-cell lineage. T-TIL fraction was defined by the ratio of Leu-2 or -3 positive cells:number of tumor cells. Eight IC-pts received allografts and 10 pts had AIDS. We found that (1) median T-TIL fraction was significantly lower in IC-NHLs than sporadic DLC (2.8% vs 11.6%; p = 0.001); (2) the frequency of cases with very low T-TIL (less than 6%) was greatest in IC-NHL (76% vs 23%; p less than 0.001); (3) deletion of one or more class I (MAS, MCA) or II (DR, DP, DQ) HLA cellular recognition antigens occurred in 14 of 19 (74%) DLC-NHL cases with low T-TIL, whereas only one (7%) of the IC-NHLs demonstrated HLA loss (p less than 0.001). These data indicate that T-TIL response in IC-NHLs is deficient and largely represents a host defect in tumor immunosurveillance, whereas low T-TIL in sporadic-DLC relates to tumor loss of HLA determinants. Strategies to augment immune response or upregulate HLA expression may be important adjuncts to improve results of cytotoxic therapy in defined pt subsets with B-cell NHL.

Keywords: Human HLA Antigens/ANALYSIS *Immune Tolerance Lymphocytes, Tumor-Infiltrating/*IMMUNOLOGY Lymphoma, B-Cell/*IMMUNOLOGY ABSTRACT

910830
M9181009

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .